Connection

Co-Authors

This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and ROBERT ORLOWSKI.
Connection Strength

0.609
  1. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med. 2013 May; 137(5):625-31.
    View in: PubMed
    Score: 0.112
  2. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers (Basel). 2023 Dec 02; 15(23).
    View in: PubMed
    Score: 0.058
  3. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. Cancer Med. 2023 07; 12(13):14293-14304.
    View in: PubMed
    Score: 0.056
  4. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
    View in: PubMed
    Score: 0.056
  5. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
    View in: PubMed
    Score: 0.040
  6. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol. 2017 06; 30(6):843-853.
    View in: PubMed
    Score: 0.037
  7. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668.
    View in: PubMed
    Score: 0.036
  8. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
    View in: PubMed
    Score: 0.035
  9. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.
    View in: PubMed
    Score: 0.034
  10. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
    View in: PubMed
    Score: 0.033
  11. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.
    View in: PubMed
    Score: 0.033
  12. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res. 2014 Aug; 38(8):896-900.
    View in: PubMed
    Score: 0.030
  13. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83.
    View in: PubMed
    Score: 0.026
  14. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011 Oct 01; 117(19):4468-74.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.